FDA Issues EUA for COVID-19 Convalescent Plasma

News
Article

FDA issued an emergency use authorization for COVID-19 convalescent plasma treatments following a report on NIH concerns about insufficient studies and data.

On Aug. 23, 2020, FDA issued an emergency use authorization (EUA) for investigational COVID-19 convalescent plasma (CCP) for the treatment of COVID-19 in hospitalized patients, noting in a clinical memorandum that “current data for the use of CCP in adult hospitalized patients with COVID-19 supports the conclusion that CCP meets the ‘may be effective’ criterion for issuance of an EUA.”

The author of the FDA memo, whose name was redacted in the released version of the document, concluded, “It is reasonable to conclude that the known and potential benefits of CCP outweigh the known and potential risks of CCP for the proposed EUA. Current data suggest the largest clinical benefit is associated with high-titer units of CCP administered early in the course of disease.”

The memo also stated the need for “adequate and well-controlled randomized trials” to demonstrate CCP efficacy, determine the optimal product attributes, and identify the patient populations suitable for use

In making the EUA decision, FDA analyzed safety and efficacy data from a National Expanded Access Treatment Protocol (EAP) program initiated by the Mayo Clinic in April 2020. More than 70,000 patients have been treated with CCP.

In an Aug. 23, 2020 press conference, FDA reported that, “Based on an evaluation of the EUA criteria and the totality of the available scientific evidence, the FDA’s Center for Biologics Evaluation and Research determined that the statutory criteria for issuing an EUA criteria were met.”

The agency further noted, “it is reasonable to believe that COVID-19 convalescent plasma may be effective in lessening the severity or shortening the length of COVID-19 illness in some hospitalized patients.”

The EUA announcement made by President Donald Trump at a White House press event on Aug. 23, 2020 was met with criticism by medical professionals concerned that the about insufficient randomized controlled clinical trials and concern about the politicization of FDA decision making. In an Aug. 19, 2020 article, the New York Times reported the leading government scientists from the National Institutes of Health warned that data from the Mayo Clinic study were not strong enough to merit an emergency authorization. On Aug. 22, the President expressed his displeasure at the lack of action in a Tweet, suggesting the delay was politically motivated.

Source:

FDA Press Release

FDA Memo

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes